Evidence map›Paper›PMID 38184157›Full record

ArticleNeuroImage2024

Direct comparison between

Ryota Satoh, Farwa Ali, Hugo Botha, Val J Lowe, Keith A Josephs, Jennifer L Whitwell

Open access · goldAbstract readComparative Study
In one paragraph

Article in NeuroImage, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 11 citations in OpenAlex.

  1. Plasma eMTBR-tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Associations of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Investigating AD and non-AD [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Article
  6. Subtracting First Principal Component May Improve 4R Tau Detectability on [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ryota SatohDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Farwa AliDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, 200 1st St SW, 55905, Rochester, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, 200 1st St SW, 55905, Rochester, MN, USA. Electronic address: whitwell.jennifer@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

Longitudinal multi-modality imaging in progressive apraxia of speech (Diversity Supplement)R01DC012519 · NIDCD · MAYO CLINIC ROCHESTER · PI Jennifer Louise Whitwell · 2013 to 2026
$7.2M
Longitudinal Multi-modal Imaging in Progressive Supranuclear Palsy SyndromesR01NS089757 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2015 to 2024
$5.6M
The neurobiology of two distinct types of progressive apraxia of speechR01DC014942 · NIDCD · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Rene Lynn Utianski · 2017 to 2026
$4.9M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseRF1NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2021 to 2021
$1.2M
Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s diseaseR01NS112153 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, WHITWELL, JENNIFER LOUISE · 2024 to 2025
$767k
NIDCD NIH HHS R01 DC012519NIDCD NIH HHS R01 DC014942NINDS NIH HHS R01 NS089757NINDS NIH HHS R01 NS112153NINDS NIH HHS RF1 NS112153
6 · The paper itself

Abstract

purposeThe pattern of flortaucipir tau PET uptake is topographically similar to the pattern of magnetic susceptibility in progressive supranuclear palsy (PSP); both with increased signal in subcortical structures such as the basal ganglia and midbrain, suggesting that they may be closely related. However, their relationship remains unknown since no studies have directly compared these two modalities in the same PSP cohort. We hypothesized that some flortaucipir uptake in PSP is associated with magnetic susceptibility, and hence iron deposition. The aim of this study was to evaluate the regional relationship between flortaucipir uptake and magnetic susceptibility and to examine the effects of susceptibility on flortaucipir uptake in PSP.

methodsFifty PSP patients and 67 cognitively normal controls were prospectively recruited and underwent three Tesla MRI and flortaucipir tau PET scans. Quantitative susceptibility maps were reconstructed from multi-echo gradient-echo MRI images. Region of interest (ROI) analysis was performed to obtain flortaucipir and susceptibility values in the subcortical regions. Relationships between flortaucipir and susceptibility signals were evaluated using partial correlation analysis in the subcortical ROIs and voxel-based analysis in the whole brain. The effects of susceptibility on flortaucipir uptake were examined by using the framework of mediation analysis.

resultsBoth flortaucipir and susceptibility were greater in PSP compared to controls in the putamen, pallidum, subthalamic nucleus, red nucleus, and cerebellar dentate (p<0.05). The ROI-based and voxel-based analyses showed that these two signals were positively correlated in these five regions (r = 0.36-0.59, p<0.05). Mediation analysis showed that greater flortaucipir uptake was partially explained by susceptibility in the putamen, pallidum, subthalamic nucleus, and red nucleus, and fully explained in the cerebellar dentate.

conclusionsThese results suggest that some of the flortaucipir uptake in subcortical regions in PSP is related to iron deposition. These findings will contribute to our understanding of the mechanisms underlying flortaucipir tau PET findings in PSP and other neurodegenerative diseases.

Indexed as

Supranuclear Palsy, ProgressiveBrainCarbolinesHumansIronPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinesIrontau ProteinsFlortaucipirIronPSPQuantitative susceptibility mappingTau PET

Identifiers

PMID38184157
PMCPMC10868646
OpenAlexW4390578452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.